BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Other Non-current Assets
Long-term assets not reported separately.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 118.3% from a year ago
Other non-current assets stood at $11.24M at the end of Q1 FY2026, up 118.3% from a year earlier and down 40.2% from the prior quarter. Over 3 fiscal years it compounded at +440.2% a year.
Context
- Other non-current assets amounted to 2.7% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +118.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 22.79M USD
- Year-over-year change
- +90591.7%
- 4-year CAGR
- +254.5%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.79M | +90591.7% |
| FY2024 | 2024-12-31 | 25.13K | -92.5% |
| FY2023 | 2023-12-31 | 332.89K | +130.3% |
| FY2022 | 2022-12-31 | 144.58K | +0.2% |
| FY2021 | 2021-12-31 | 144.28K | — |
Other Non-current Assets vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +118.3% is the 3rd highest of 10, against a peer median of +3.0%.
- Other non-current assets amounts to 2.7% of total assets for BBOT, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $88.45M USD | +6190.8% | +421.4% | 14.3% |
| Mar 2026 | $25.03M USD | +1.3% | +345.9% | 8.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $11.24M USD | +118.3% | +440.2% | 2.7% |
| Sep 2026 | $8.93M USD | +3.0% | -47.1% | 4.3% | |
| Aug 2026 | $8.74M USD | +4.7% | +19.1% | 0.7% | |
| Mar 2026 | $7.49M USD | +1269.8% | +20.3% | 3.0% | |
| Sep 2026 | $2.39M USD | -1.8% | -10.7% | 0.2% | |
| Mar 2026 | CHF 793.62K CHF | +56.2% | +119.8% | 0.3% | |
| Jun 2026 | $689K USD | -12.1% | -6.7% | 0.1% | |
| Mar 2026 | $256K USD | +0.0% | +0.0% | 0.1% | |
| Peer median (excluding BBOT) | — | +3.0% | +19.1% | 0.7% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.